CCL17 and neoplasm: TGF-β (24, 25) and the CCL17,22/CCR4 (26) axis may be playing a role in this upregulation of Tregs after XRT, although it is unclear if this is due to Tregs that survived the initial doses of XRT or their recruitment to the tumor site after XRT.